Resources from the same session
Time to response in patients with ALK+ NSCLC receiving alectinib in the phase II NP28673 and NP28761 studies
Presenter: Leena Gandhi
Session: NSCLC, metastatic
Resources:
Abstract
Phase I/II trial of X-396 in patients (pts) with ALK+ non-small cell lung cancer (NSCLC): Correlation with plasma and tissue genotyping and response to therapy (tx)
Presenter: Leora Horn
Session: NSCLC, metastatic
Resources:
Abstract
Phase 2 study of lenvatinib (LN) in patients (Pts) with RET fusion-positive adenocarcinoma of the lung
Presenter: Vamsidhar Velcheti
Session: NSCLC, metastatic
Resources:
Abstract
Phase 1/2 study of the safety and clinical activity of durvalumab in patients with non-small cell lung cancer (NSCLC)
Presenter: Scott Antonia
Session: NSCLC, metastatic
Resources:
Abstract
Pembrolizumab (pembro) vs docetaxel (doce) for previously treated, PD-L1–expressing NSCLC: Updated outcomes of KEYNOTE-010
Presenter: Roy S. Herbst
Session: NSCLC, metastatic
Resources:
Abstract
Overall health status (HS) in patients (pts) with advanced (adv) non-squamous (NSQ) NSCLC treated with nivolumab (nivo) or docetaxel (doc) in CheckMate 057
Presenter: Martin Reck
Session: NSCLC, metastatic
Resources:
Abstract
LURET study: Phase 2 study of vandetanib in patients with advanced RET-rearranged non-small cell lung cancer (NSCLC)
Presenter: Atsushi Horiike
Session: NSCLC, metastatic
Resources:
Abstract
Lung sarcomatoid carcinoma (LSC) harbors targetable genomic alterations and high mutational burden as observed by comprehensive genomic profiling (CGP)
Presenter: Balazs Halmos
Session: NSCLC, metastatic
Resources:
Abstract
Long-term outcomes with nivolumab (Nivo) vs docetaxel (Doc) in patients (Pts) with advanced (Adv) NSCLC: CheckMate 017 and CheckMate 057 2-y update
Presenter: Fabrice Barlesi
Session: NSCLC, metastatic
Resources:
Abstract
Invited discussant abstracts LBA48, 1215PD, 1216PD, 1217PD, and 1218PD
Presenter: Fiona Blackhall
Session: NSCLC, metastatic
Resources:
Presentation
Webcast
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
-
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.